Lynette F. Smith

Array ( [id] => 3862425 [patent_doc_number] => 05837264 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-11-17 [patent_title] => 'Potentiation of immunogenic response' [patent_app_type] => 1 [patent_app_number] => 8/470278 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 2949 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/837/05837264.pdf [firstpage_image] =>[orig_patent_app_number] => 470278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3643616 [patent_doc_number] => 05683702 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-11-04 [patent_title] => 'Primary and secondary immunization with different physio-chemical forms of antigen' [patent_app_type] => 1 [patent_app_number] => 8/470767 [patent_app_country] => US [patent_app_date] => 1995-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 1432 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/683/05683702.pdf [firstpage_image] =>[orig_patent_app_number] => 470767 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3808635 [patent_doc_number] => 05788968 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-08-04 [patent_title] => 'Methods and compositions for suppressing allograft rejection in mammals' [patent_app_type] => 1 [patent_app_number] => 8/461661 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 6970 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/788/05788968.pdf [firstpage_image] =>[orig_patent_app_number] => 461661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3960502 [patent_doc_number] => 05885578 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-23 [patent_title] => 'Prevention and treatment of retroviral disease' [patent_app_type] => 1 [patent_app_number] => 8/469739 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4954 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/885/05885578.pdf [firstpage_image] =>[orig_patent_app_number] => 469739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3764877 [patent_doc_number] => 05733550 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-03-31 [patent_title] => 'Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with .beta.-microglobulin' [patent_app_type] => 1 [patent_app_number] => 8/461213 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 8471 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/733/05733550.pdf [firstpage_image] =>[orig_patent_app_number] => 461213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3863052 [patent_doc_number] => 05795955 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-08-18 [patent_title] => 'Tandem synthetic HIV-1 peptides' [patent_app_type] => 1 [patent_app_number] => 8/463966 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15877 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/795/05795955.pdf [firstpage_image] =>[orig_patent_app_number] => 463966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4081600 [patent_doc_number] => 06017543 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 2000-01-25 [patent_title] => 'Prevention and treatment of retroviral disease' [patent_app_type] => 1 [patent_app_number] => 8/467302 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 18 [patent_no_of_words] => 8157 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/017/06017543.pdf [firstpage_image] =>[orig_patent_app_number] => 467302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3921014 [patent_doc_number] => 05876731 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-03-02 [patent_title] => 'Tandem synthetic HIV-1 Peptides' [patent_app_type] => 1 [patent_app_number] => 8/462507 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15674 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/876/05876731.pdf [firstpage_image] =>[orig_patent_app_number] => 462507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1533749 [patent_doc_number] => 06410701 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2002-06-25 [patent_title] => 'Human neuropeptide receptor' [patent_app_type] => B1 [patent_app_number] => 08/462509 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 18221 [patent_no_of_claims] => 169 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/410/06410701.pdf [firstpage_image] =>[orig_patent_app_number] => 08462509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3777131 [patent_doc_number] => 05817754 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-10-06 [patent_title] => 'Tandem synthetic HIV-1 peptide' [patent_app_type] => 1 [patent_app_number] => 8/464329 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15653 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/817/05817754.pdf [firstpage_image] =>[orig_patent_app_number] => 464329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3697203 [patent_doc_number] => 05674502 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1997-10-07 [patent_title] => 'Cross-reactive influenza a immunization' [patent_app_type] => 1 [patent_app_number] => 8/462963 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6932 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/674/05674502.pdf [firstpage_image] =>[orig_patent_app_number] => 462963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4063332 [patent_doc_number] => 05895650 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1999-04-20 [patent_title] => 'Prevention and treatment of retroviral disease' [patent_app_type] => 1 [patent_app_number] => 8/467334 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 8046 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/895/05895650.pdf [firstpage_image] =>[orig_patent_app_number] => 467334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3771839 [patent_doc_number] => 05773573 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-06-30 [patent_title] => 'HIV peptides' [patent_app_type] => 1 [patent_app_number] => 8/461564 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8065 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/773/05773573.pdf [firstpage_image] =>[orig_patent_app_number] => 461564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3738687 [patent_doc_number] => 05800822 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-09-01 [patent_title] => 'Tandem synthetic HIV-1 peptides' [patent_app_type] => 1 [patent_app_number] => 8/465217 [patent_app_country] => US [patent_app_date] => 1995-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15698 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/800/05800822.pdf [firstpage_image] =>[orig_patent_app_number] => 465217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3845005 [patent_doc_number] => 05718904 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-02-17 [patent_title] => 'Adjuvants for viral vaccines' [patent_app_type] => 1 [patent_app_number] => 8/459600 [patent_app_country] => US [patent_app_date] => 1995-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2664 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/718/05718904.pdf [firstpage_image] =>[orig_patent_app_number] => 459600 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3824311 [patent_doc_number] => 05759769 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-06-02 [patent_title] => 'Tandem synthetic HIV-1 peptides' [patent_app_type] => 1 [patent_app_number] => 8/460602 [patent_app_country] => US [patent_app_date] => 1995-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 15602 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 500 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/759/05759769.pdf [firstpage_image] =>[orig_patent_app_number] => 460602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 3784105 [patent_doc_number] => 05736319 [patent_country] => US [patent_kind] => NA [patent_issue_date] => 1998-04-07 [patent_title] => 'Attenuated gentically-engineered pseudorabies virus S-PRV-155 and uses thereof' [patent_app_type] => 1 [patent_app_number] => 8/456509 [patent_app_country] => US [patent_app_date] => 1995-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9497 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/05/736/05736319.pdf [firstpage_image] =>[orig_patent_app_number] => 456509 [rel_patent_id] =>[rel_patent_doc_number] =>)